In a study on immunotherapy for lung cancer, researchers discovered that patients with PD-L1 1% but a subgroup of 10 mutations/Mb in the combination chemotherapy group had a better objective response rate (ORR) and median progression-free survival (median PFS, mPFS) with the immune combination regimen CheckMate 227 (Hellmann et al., 2018). The gene discussed is CD274; the disease is lung carcinoma.